FibroBiologics, Inc. Common Stock (FBLG) - Total Assets
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) holds total assets worth $8.74 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore FBLG operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
FibroBiologics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See FBLG net asset value for net asset value and shareholders' equity analysis.
FibroBiologics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2025)
FibroBiologics, Inc. Common Stock's total assets of $8.74 Million consist of 86.5% current assets and 13.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is FibroBiologics, Inc. Common Stock worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: FibroBiologics, Inc. Common Stock's current assets represent 86.5% of total assets in 2025, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 85.0% of total assets in 2025, down from 87.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
FibroBiologics, Inc. Common Stock Competitors by Total Assets
Key competitors of FibroBiologics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
FibroBiologics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.78 | 1.23 | 0.37 |
| Quick Ratio | 0.78 | 1.23 | 0.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.48 Million | $1.52 Million | $-4.45 Million |
FibroBiologics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between FibroBiologics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 179.87 |
| Latest Market Cap to Assets Ratio | 1.37 |
| Asset Growth Rate (YoY) | 39.1% |
| Total Assets | $16.45 Million |
| Market Capitalization | $22.48 Million USD |
Valuation Analysis
Above Book Valuation: The market values FibroBiologics, Inc. Common Stock's assets above their book value (1.37x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: FibroBiologics, Inc. Common Stock's assets grew by 39.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of FibroBiologics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $16.45 Million | +39.12% |
| 2024-06-30 | $11.82 Million | +145.05% |
| 2023-06-30 | $4.82 Million | +930.77% |
| 2022-06-30 | $468.00K | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.